Biopharma Quarterly Dealmaking Statistics, Q2 2016
A look at financing, M&A and alliance activity April–June 2016
Executive Summary
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
You may also be interested in...
Spark Therapeutics Now Targets 2017 For US Approval Of First Retinal Gene Therapy
Two manufacturing control assays have taken longer to develop than previously thought, putting back completion of a BLA submission to early 2017 for US company Spark Therapeutics, while further progress has been made in the company’s early-stage hemophilia gene therapy program.
Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017
Bioverativ was unveiled as the name for Biogen’s spin out; an initial Form 10 registration will be filed with SEC later this week.
Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth
Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.